There are currently 543 clinical trials in Madison, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Wisconsin, University of Wisconsin Hospital and Clinics, University of Wisconsin-Madison and University of Wisconsin Carbone Cancer Center - University Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
NCT04575935
Recruiting
This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant chemotherapy). MIS is a surgical procedure that uses small incision(s) and is intended to produce minimal blood loss and pain for the patient. Laparotomy is a surgical procedure which allows the doctors to remove some or all of the tumor and check if the disea... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Serous Neoplasm, Fallopian Tube Transitional Cell Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8
Register for Updates
US Imaging for the Assessment of LUTS
NCT06323109
Recruiting
The purpose of this research is to develop an ultrasound (US) based urodynamics (UDS) evaluation of voiding based on successful magnetic resonance imaging (MRI)-UDS evaluation. Both US and MRI are non-invasive imaging techniques, but US is a more cost-effective and widely available technology. 80 participants will be enrolled and will be on study for up to 2.5 hours (1.5 hour MRI and 1 hour US).
Gender:
MALE
Ages:
Between 18 years and 80 years
Trial Updated:
03/12/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Lower Urinary Tract Symptoms, BPH
Register for Updates
Testing STAR and TexSTAR: A Video and Text Messaging Intervention
NCT06456190
Recruiting
This NIDA-funded HEAL Initiative: Opioid Use Disorder Care Pathways for Individuals with Histories of Exposure to Violence R61 seeks to develop and test a brief video intervention to deliver during Sexual Assault Nurse Examiner (SANE) care and a brief text messaging intervention to deliver in the month after the assault to prevent the onset or escalation of PTSD and opioid misuse among survivors of sexual assault.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
03/12/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Sexual Violence, Posttraumatic Stress Disorder, Opioid Use, Opioid Misuse
Register for Updates
Gastroschisis Outcomes of Delivery (GOOD) Study
NCT02774746
Recruiting
The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7 weeks in stable patients with gastroschisis is superior to observation and expectant management with a goal of delivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we will complete a randomized, prospective, multi-institutional trial across NAFTNet-affiliated institutions. Patients may be enrolled in the study any time prior to 33 weeks, but will be randomized at 33 weeks to delivery at 35 weeks o... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: University of Wisconsin - Madison, Madison, Wisconsin
Conditions: Gastroschisis
Register for Updates
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404
Recruiting
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
03/11/2025
Locations: University of Wisconsin, Madison, Wisconsin +1 locations
Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Hemophilia, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Register for Updates
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
NCT05477823
Recruiting
The purpose of this study is to evaluate the imaging and gene expression biomarkers in prostate cancer. Participants have high-risk prostate cancer and have indicated they will undergo external beam radiation therapy, brachytherapy, and androgen deprivation therapy (EBRT+BTX+ADT). Participants can expect to be in this study for up to 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Prostate Cancer
Register for Updates
Effectiveness of an Automated Falls-Risk Screening and Referral Tool in the Emergency Department (ED)
NCT05810064
Recruiting
The purpose of this retrospective cohort study is to evaluate the effectiveness of an EHR-based clinical decision support system (CDS) for automatically screening older adult ED patients for risk of future falls and providing ED clinicians opportunity to place referrals orders to the UW Health Mobility and Falls Clinic for those at highest risk prior to discharge. This CDS tool has already been implemented at the UW Hospital ED, and as a QI initiative will be implemented in a staged process at... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/10/2025
Locations: East Madison Hospital, Madison, Wisconsin +1 locations
Conditions: Falls-Risk
Register for Updates
Patient Perspectives of an Automated Falls-Risk Screening and Referral Tool in the Emergency Department (ED)
NCT05846685
Recruiting
The purpose of the overall study to evaluate implementation-related outcomes of a falls-risk clinical decision support (CDS) system using patient electronic health records (EHR) data to automatically screen and identify older adult ED patients at high risk of future falls and allowing ED clinicians to place referral orders to the UW Health Mobility and Falls clinic. This CDS tool has already been implemented at the UWHC ED, and will be additionally implemented at The American Center and Swedish... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/10/2025
Locations: The American Center Emergency Department, Madison, Wisconsin +1 locations
Conditions: Falls-Risk
Register for Updates
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
NCT06079398
Recruiting
This trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs. placebo), placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 μg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly for 52 weeks in infants with genetically verified heterozygous ACH, aged 0 to \< 2 years at the time of randomization.
Gender:
ALL
Ages:
Between 0 years and 2 years
Trial Updated:
03/10/2025
Locations: Ascendis Investigational Site, Madison, Wisconsin
Conditions: Achondroplasia
Register for Updates
Outcomes and Cosmesis With Whole Breast Irradiation and Boost
NCT06295744
Recruiting
This study is being done to evaluate cosmetic, patient-reported outcome measures (PROMs), and toxicities for women undergoing ultra-short whole breast irradiation (WBI) therapy with simultaneous integrated boost (SIB). 50 participants will be on study for up to 60 months.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: UW Carbone Cancer Center, Madison, Wisconsin
Conditions: Early-stage Breast Cancer
Register for Updates
Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform
NCT06344416
Recruiting
Primary Objective: • To assess the persistence of ReX technology platform use, measured by the percentage (%) of participants who used ReX: 1) throughout the study period and 2) before the treatment discontinuation. Secondary Objective: • To evaluate the impact of the ReX technology platform on ribo treatment duration and ribo dose taking adherence as compared to control group.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Lumicera, Madison, Wisconsin
Conditions: Any Solid Oral Medication
Register for Updates
In Vivo Liquid Biopsy of Melanoma (Cytophone)
NCT06488365
Recruiting
The Cytophone is a first in the world patented system to identify and count single circulating melanoma cells in blood circulation inside the human body. The Cytophone has a unique capability to find rare melanoma cells in the blood by an assessment of 100-500 times greater amounts of blood volume than routine blood tests. The important benefit of the Cytophone diagnosis is that the test does not require injection or any skin incision (i.e., non-invasiveness). The goal of this clinical trial is... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/10/2025
Locations: SSM Health Dean Medical Group Specialty Services, Madison, Wisconsin
Conditions: Melanoma, Circulating Tumor Cells, Metastatic Melanoma, Diagnosis
Register for Updates